Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor‐2 high expressing salivary duct carcinomas-Reference-Cited by-同舟云学术

Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor‐2 high expressing salivary duct carcinomas

Published:2018-11-26 Issue:12 Volume:40 Page:E100-E106
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head Neck

Author:

Park Jong Chul¹,Ma T. Martin²^ORCID,Rooper Lisa³,Hembrough Todd⁴,Foss Robert D.⁵,Schmitt Nicole C.⁶^ORCID,Sawhney Rishi⁷,Flanders Aaron⁸,Kang Hyunseok²^ORCID

Affiliation:

1. Department of MedicineHarvard Medical School and Massachusetts General Hospital Boston Massachusetts

2. Department of OncologyThe Johns Hopkins University School of Medicine Baltimore Maryland

3. Department of PathologyThe Johns Hopkins University School of Medicine Baltimore Maryland

4. NantOmics Rockville Maryland

5. Department of DermatologyThe Johns Hopkins University School of Medicine Baltimore Maryland

6. Department of Otolaryngology ‐ Head and Neck SurgeryThe Johns Hopkins University School of Medicine Baltimore Maryland

7. Bayhealth Cancer Institute Dover Maryland

8. Department of Hematology/OncologyNaval Medical Center Portsmouth Virginia

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.25392

Reference26 articles.

1. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database

2. Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients

3. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer

4. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

5. Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy;Modern Pathology;2023-10

2. Targeting human EGFR 2 (HER2) in salivary gland carcinoma;Expert Review of Anticancer Therapy;2023-05-16

3. The Epigenesis of Salivary Glands Carcinoma: From Field Cancerization to Carcinogenesis;Cancers;2023-03-31

4. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma;Oral Oncology;2022-02

5. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing;Modern Pathology;2021-12-28